Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Osimertinib (Primary) ; Savolitinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SACHI
- Sponsors Hutchison MediPharma; HUTCHMED
- 28 Feb 2023 According to a HUTCHMED media release, enrollment expected to be completed in late-2024.
- 29 Nov 2021 Status changed from not yet recruiting to recruiting.
- 22 Nov 2021 According to a HUTCHMED media release, first patient received their first dose